Inhibition by omeprazole of proguanil metabolism: Mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 730-738

  Funck Brentano, Christian ^a   Becquemont, Laurent ^b   Leneveu, Anne ^c   Roux, Annie ^c   Jaillon, Patrice ^a   Beaune, Philippe ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c CHU Ambroise Pare   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; OMEPRAZOLE; PROGUANIL; TESTOSTERONE; TROLEANDOMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GASTRODUODENAL ULCER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER MICROSOME; MALARIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; REFERENCE VALUES; TRIAZINES;

EID: 0030899603     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. ANDERSSON, T., ANDRÉN, K., CEDERBERG, C., LAGERSTRÖM, P.-O., LUNDBORG, P. AND SKANBERG, I.: Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol. 29: 557-563, 1990a.
2. ANDERSSON. T., MINERS, J. O., VEHONESE, M. E. AND BIRKETT, D. J.: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37: 597-604, 1994.
3. ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEY-AKUL, W., MEYER, U. A. AND BIRKETT, D. J.: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism, Br. J. Clin. Pharmacol. 36: 521-530, 1993.
4. ANDERSSON, T., REGARDH, C. G., DAHL-PUUSTINEN, M. J. AND BERTILSSON, L.: Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug. Monit. 12: 415-416, 1990b.
5. BALIAN, J. D., SUKHOVA, N., HARRIS, J. W., HEWETT, J., PICKLE, L., GOLDSTEIN, J. A., WOOSLEY, R. L. AND FLOCKHART, D. A.: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin. Pharmacol. Ther. 57: 662-669, 1995.
6. BELLOC, A., BAIRD, S., COSME, J., LECOEUR, S., GAUTIER, J.-C., CHALLINE, D., DE WAZIERS, I., FLINOIS, J.-P. AND BEAUNE, P.: Human cytochrome P450 expressed in Escherichia coli: Production of specific antibodies. Toxicology 106: 207-219, 1996.
7. BIRKETT, D. J., REES, D., ANDERSSON, T., GONZALES, F. J., MINERS, J. O. AND VERONESE, M. E.: In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br. J. Clin. Pharmacol. 37: 413-420, 1994.
8. BOTSCH, S., GAUTIER, J.-C., BEAUNE, P., EICHELBAUM, M. AND KROEMER, H.-K.: Identification and characterization of the P-450 enzymes involved in the N-dealkylation of propafenone: A molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43: 120-126, 1993.
9. BRØSEN, K., SKJELBO, E. AND FLACHS, H.: Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br. J. Clin. Pharmacol. 36: 105-108, 1993.
10. CHANG, M., TYBRING, G., DAHL, M.-L., GÖTHARSON, E., SAGAR, M., SEENSALU, R. AND BERTILSSON, L.: Interphenotype differences in disposition and effect on gastrin levels of omeprazole: Suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol. 39: 511-518, 1995.
11. CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. AND ISHIZAKI, T.: Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266: 52-59, 1993.
12. FUNCK-BRENTANO, C., BECQUEMONT, L., KROEMER, H. K., BÜHL, K., KNEBEL, N. G., EICHELBAUM, M. AND JAILLON, P.: Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin. Pharmacol. Ther. 55: 256-269, 1994.
13. FUNCK-BKENTANO, C., Bosco, O., JACQZ-AIGRAIN, E., KEUNDJIAN, A. AND JAILLON, P.: Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin. Pharmacol. Ther. 51: 507-512, 1992.
14. FUNCK-BRENTANO, C., KROEMER, H. K., PAVLOU, H., WOOSLEY, R. L. AND RODEN, D. M.: Genetically-determined interaction between propafenone and low dose quinidine: Role of active metabolites in modulating net drug effect. Br. J. Clin. Pharmacol. 27: 435-444, 1989a.
15. FUNCK-BRENTANO, C., TURGEON, J., WOOSLEY, R.-L. AND RODEN, D. M.: Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: Influence of genetic polymorphism. J. Pharmacol. Exp. Ther. 249: 134-142, 1989b.
16. GALBRAITH, R. A. AND MICHNOVICZ, J. J.: Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. Pharmacology 47: 8-12, 1993.
17. GOLDSTEIN, J. A., FALETTO, M. B., ROM KES-S PARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. AND GHANAYEM B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752, 1994.
18. HELSBY, N. A., WARD, S. A., EDWARDS, G., HOWELLS, R. E. AND BRECKENRIDGE, A. M.: The pharmacokinetics and activation of proguanil in man: Consequences of variability in drug metabolism. Br. J. Clin. Pharmacol. 30: 593-598, 1990a.
19. HELSBY, N. A., WARD, S. A., HOWELLS, R. E. AND BRECKENRIDGE, A. M.: In vitro metabolism of the biguanide antimalarials in human liver microsomes: Evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br. J. Clin. Pharmacol. 30: 287-291, 1990b.
20. JURIMA, M., INABA, T., KADAR, D. AND KALOW, W.: Genetic polymorphism of mephenytoin p(4′)-hydroxylation: Difference between Orientals and Caucasians. Br. J. Clin. Pharmacol. 19: 483-487, 1985.
21. KATO, R. AND YAMAZOE, Y.: The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 4: 359-362, 1994.
22. KERLAN, V., DREANO, Y., BERCOVICI, J.-P., BEAUNE, P., FLOCH, H. H. AND BERTOU, F.: Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem. Pharmacol. 44: 1745-1756, 1992.
23. KREMERS, P., BEAUNE, P., CRESTEIL, T., DE GRAEVE, J., COLUMELLI, S., LEROUX, J.-P. AND GIELEN, J. E.: Cytochrome P450 monooxygenase activities in human and rat liver microsomes. Eur. J. Biochem. 118: 599-606, 1981.
24. KROEMER, H. K., ECHIZEN, H., HEIDEMANN, H. AND EICHELBAUM, M.: Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260: 1052-1057, 1992.
25. LAEMMLI, U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature (Lond.) 227: 680-685, 1970.
26. MACGREGOR, G. A., SAGNELLA, G. A. AND MACRAE, K. D.: Misleading paper about misleading statistics. Lancet 1: 926-927, 1985.
27. MINERS, J. O. AND BIRKETT, D. J.: The misuse of urinary metabolite excretion data in drug metabolism studies. Pharmacogenetics 3: 58-59, 1993.
28. MINERS, J. O., VERONESE, M. E. AND BIRKETT, D. J.: In vitro approaches for the prediction of human drug metabolism. Annu. Rep. Med. Chem. 29: 307-316, 1994.
29. MOTULSKY, H. J. AND RANSNAS, L. A.: Fitting curves to data using nonlinear regression: A practical and nonmathematical review. FASEB J. 1: 365-374, 1987.
30. NEWTON, D. J., WANG, R. W. AND Lu, A. Y. H.: Cytochrome P450 inhibitors: Evaluation of the specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23: 154-158, 1995
31. PARTOVIAN, C., JACQZ-AIGRAIN, E., KEUNDJIAN, A., JAILLON, P. AND FUNCK-BRENTANO, C.: Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol. Ther. 58: 257-263, 1995.
32. REGÅRDH, C. G., GABRIELSSON, M., HOFFMAN, K.-J., LÖFBERG, I. AND SKANBERG, I.; Pharmacokinetics and metabolism of omeprazole in animals and man: An overview, Scand. J. Gastroenterol. 20: suppl. 108, 79-94, 1985.
33. SCHELLENS, J. H. M., VAN DER WART, J. H. F., BRUGMAN, M. AND BREIMER, D. D.: Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cock-tail" study design. J. Pharmacol. Exp. Ther. 249: 638-645, 1989.
34. SCHOENE, B., FLEISCHMANN, R. A., REMMER, H. AND VAN OLDER-SHAWSEN, H. F.: Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur. J. Clin. Pharmacol. 4: 65-73, 1972.
35. SETIABUDY, R., KUSAKA, M., CHIBA, K., DARMANSJAH, I. AND ISHIZAKI, T.: Metabolic disposition of proguanil in extensive and poor metabolizers of Smephenytoin 4′-hydroxylation recruited from an Indonesian population. Br. J. Clin. Pharmacol. 39: 297-303, 1995.
36. SKJELBO, E., MUTABINGWA, T. K., BYGBJERG, I., NIELSEN, K. K., GRAM, L. F. AND BRØSEN, K.: Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin. Pharmacol. Ther. 59: 304-311, 1996.
37. SOHN, D. R., KOBAYASHI, K., CHIBA, K., LEE, K. H., SHIN, S. G. AND ISHIZAKI, T.: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 262: 1195-1202, 1992.
38. SUMNER, D. J., MEREDITH, P. A., HOWIE, C. A. AND ELLIOTT, H. L.: Initial blood pressure as a predictor of the response to antihypertensive therapy. Br. J. Clin. Pharmacol. 26: 715-720, 1988.
39. TATEISHI, T., GRAHAM, S. G., KRIVORUK, Y. AND WOOD, A. J. J.: Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test Br. J. Clin. Pharmacol. 40: 411-412, 1995.
40. TAYLOR, R. B., MOODY, R. R. AND OCHEKPE, N. A.: Determination of proguanil and its metabolites, cycloguanil and 4-chlorophenylbiguanide, in plasma, whole blood and urine by high performance liquid chromatography. J. Chromatogr. 416: 394-399, 1987.
41. VANDEN BRANDEN, M., RING, B. J., BINKLEY, S. N. AND WRIGHTON, S. A.: Interaction of human cytochromes P450 in vitro with LY 307640, a gastric proton pump inhibitor. Pharmacogenetics 6: 81-91, 1996.
42. WALKER, D., FLINOIS, J.-P., MONKMAN, S. C., BELOC, C., BODDY, A. V., CHOLERTON, S., DALY, A. K., LIND, M. J., PEARSON, A. D. J., BEAUNE, P. AND IDLE, J. R.: Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol 47: 1157-1163, 1994.
43. WALLE, T., WALLE, U. K., OLANOFF, L. S. AND CONRADI, E. C.: Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br. J. Clin. Pharmacol. 22: 317-323, 1986.
44. WATKINS, W. M., MBERU, E. K., NEVILL, C. G., WARD, S. A., BRECKENRIDGE, A. M. AND KOECH, D. K.: Variability in the metabolism of proguanil to the active, metabolite cycloguanil in healthy Kenyan adults. Trans. R. Soc. Trop. Med. Hyg. 84: 492-495, 1990.
45. WATKINS, W. M., SIXSMITH, D. G. AND CHULAY, J. D.: The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann. Trop. Med. Parasitol. 78: 273-278, 1984.
46. WILKINSON, G. R., GUENGERICH, F. P. AND BRANCH, R. A.: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43: 53-76, 1989.
47. WRIGHT, J. D., HELSBY, N. A. AND WARD, S. A.: The role of S-mephenytom hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides Br. J. Clin. Pharmacol. 39: 441-444, 1995.
48. YEO, A. E. T., EDSTEIN, M. D., SHANKS, G. D. AND RIECKMANN, K. H.: A statistical analysis of the antimalarial activity of proguanil and cycloguanil in human volunteers. Ann. Trop. Med. Parasitol. 88: 587-594, 1994.